Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1005, pseudogene (RNU6-1005P) is a pseudogene derived from the highly conserved U6 small nuclear RNA (snRNA), which is a core component of the spliceosome involved in pre-mRNA splicing in eukaryotes[1][3]. As a pseudogene, RNU6-1005P is not thought to be transcribed into a functional RNA or protein and does not play an active role in cellular processes[1]. U6 snRNA, from which this pseudogene derives, is essential for catalyzing intron removal from pre-mRNA during splicing, but numerous copies exist in vertebrate genomes as both functional genes and pseudogenes due to gene duplication and retrotransposition events[3][4]. RNU6-1005P itself does not have any established therapeutic significance, disease role, associated drugs, or biomarker status[1]. Its presence reflects evolutionary redundancy and the high importance of the spliceosome for eukaryotic gene expression, but RNU6-1005P does not itself encode an active molecule or target[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1005, pseudogene (RNU6-1005P).